BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Slivicki RA, Iyer V, Mali SS, Garai S, Thakur GA, Crystal JD, Hohmann AG. Positive Allosteric Modulation of CB1 Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward. Front Mol Neurosci 2020;13:54. [PMID: 32410959 DOI: 10.3389/fnmol.2020.00054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Dodu JC, Moncayo RK, Damaj MI, Schlosburg JE, Akbarali HI, O'Brien LD, Kendall DA, Wu Z, Lu D, Lichtman AH. The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice. J Pharmacol Exp Ther 2022;380:1-14. [PMID: 34625464 DOI: 10.1124/jpet.121.000723] [Reference Citation Analysis]
2 Bruehl S, Burns JW, Koltyn K, Gupta R, Buvanendran A, Edwards D, Chont M, Wu YH, Stone A. Does aerobic exercise training alter responses to opioid analgesics in individuals with chronic low back pain? A randomized controlled trial. Pain 2021;162:2204-13. [PMID: 33394881 DOI: 10.1097/j.pain.0000000000002165] [Reference Citation Analysis]
3 Onofrychuk TJ, Cai S, McElroy DL, Roebuck AJ, Greba Q, Garai S, Thakur GA, Laprairie RB, Howland JG. Effects of the cannabinoid receptor 1 positive allosteric modulator GAT211 and acute MK-801 on visual attention and impulsivity in rats assessed using the five-choice serial reaction time task. Prog Neuropsychopharmacol Biol Psychiatry 2021;109:110235. [PMID: 33373679 DOI: 10.1016/j.pnpbp.2020.110235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Lutz B. Neurobiology of cannabinoid receptor signaling
. Dialogues Clin Neurosci 2020;22:207-22. [PMID: 33162764 DOI: 10.31887/DCNS.2020.22.3/blutz] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
5 Che T. Advances in the Treatment of Chronic Pain by Targeting GPCRs. Biochemistry 2021;60:1401-12. [PMID: 33186495 DOI: 10.1021/acs.biochem.0c00644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Garai S, Schaffer PC, Laprairie RB, Janero DR, Pertwee RG, Straiker A, Thakur GA. Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure. Bioorg Med Chem 2021;50:116421. [PMID: 34634617 DOI: 10.1016/j.bmc.2021.116421] [Reference Citation Analysis]
7 Finn DP, Haroutounian S, Hohmann AG, Krane E, Soliman N, Rice ASC. Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. Pain 2021;162:S5-S25. [PMID: 33729211 DOI: 10.1097/j.pain.0000000000002268] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
8 Garai S, Leo LM, Szczesniak AM, Hurst DP, Schaffer PC, Zagzoog A, Black T, Deschamps JR, Miess E, Schulz S, Janero DR, Straiker A, Pertwee RG, Abood ME, Kelly MEM, Reggio PH, Laprairie RB, Thakur GA. Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. J Med Chem 2021;64:8104-26. [PMID: 33826336 DOI: 10.1021/acs.jmedchem.1c00040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Kasai S, Nishizawa D, Hasegawa J, Fukuda K, Ichinohe T, Nagashima M, Hayashida M, Ikeda K. Short Tandem Repeat Variation in the CNR1 Gene Associated With Analgesic Requirements of Opioids in Postoperative Pain Management. Front Genet 2022;13:815089. [DOI: 10.3389/fgene.2022.815089] [Reference Citation Analysis]
10 Mielnik CA, Lam VM, Ross RA. CB1 allosteric modulators and their therapeutic potential in CNS disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2021;106:110163. [DOI: 10.1016/j.pnpbp.2020.110163] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Morris G, Walder K, Kloiber S, Amminger P, Berk M, Bortolasci CC, Maes M, Puri BK, Carvalho AF. The endocannabinoidome in neuropsychiatry: Opportunities and potential risks. Pharmacol Res 2021;170:105729. [PMID: 34119623 DOI: 10.1016/j.phrs.2021.105729] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lin X, Xu Z, Carey L, Romero J, Makriyannis A, Hillard CJ, Ruggiero E, Dockum M, Houk G, Mackie K, Albrecht PJ, Rice FL, Hohmann AG. A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse. Pain 2021. [PMID: 35001054 DOI: 10.1097/j.pain.0000000000002502] [Reference Citation Analysis]
13 Bodnar RJ. Endogenous opiates and behavior: 2020. Peptides 2022. [DOI: 10.1016/j.peptides.2022.170752] [Reference Citation Analysis]
14 Iyer V, Woodward TJ, Pacheco R, Hohmann AG. A limited access oral oxycodone paradigm produces physical dependence and mesocorticolimbic region-dependent increases in DeltaFosB expression without preference. Neuropharmacology 2021;205:108925. [PMID: 34921830 DOI: 10.1016/j.neuropharm.2021.108925] [Reference Citation Analysis]
15 Leo LM, Abood ME. CB1 Cannabinoid Receptor Signaling and Biased Signaling. Molecules 2021;26:5413. [PMID: 34500853 DOI: 10.3390/molecules26175413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Iyer V, Slivicki RA, Thomaz AC, Crystal JD, Mackie K, Hohmann AG. The cannabinoid CB2 receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence. Eur J Pharmacol 2020;886:173544. [PMID: 32896549 DOI: 10.1016/j.ejphar.2020.173544] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
17 Paton KF, Luo D, La Flamme AC, Prisinzano TE, Kivell BM. Sex Differences in Kappa Opioid Receptor Agonist Mediated Attenuation of Chemotherapy-Induced Neuropathic Pain in Mice. Front Pharmacol 2022;13:813562. [DOI: 10.3389/fphar.2022.813562] [Reference Citation Analysis]
18 Datta U, Kelley LK, Middleton JW, Gilpin NW. Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats. Psychopharmacology (Berl) 2020;237:3729-39. [PMID: 32857187 DOI: 10.1007/s00213-020-05650-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Zieglgänsberger W, Brenneisen R, Berthele A, Wotjak CT, Bandelow B, Tölle TR, Lutz B. Chronic Pain and the Endocannabinoid System: Smart Lipids – A Novel Therapeutic Option? Med Cannabis Cannabinoids. [DOI: 10.1159/000522432] [Reference Citation Analysis]